Midi Health Tirzepatide Review: Visits, Drugs & Costs (2026)

Midi Health stands out for placing weight care within women’s midlife health, rather than presenting medication as a standalone subscription. That can be useful when weight concerns overlap with perimenopause or menopause care. Its pricing requires extra attention: clinician visits and medication are separate expenses, and the cheapest oral product is not equivalent to an injectable prescription.

Visits come first in the budget

Midi’s weight-management page describes clinician visits, assessment and follow-up within its women’s health service. It advertises care across all fifty states, while individual medication availability can differ. That program-level statement is not a guarantee that a specific formulation can be dispensed to every patient.¹

The pricing-and-insurance page lists self-pay visits at $250 initially and $150 for follow-ups. Commercial insurance may cover visits depending on the plan and network; deductibles and other patient costs can still apply. Medication coverage is a separate question from whether a Midi visit is covered.²

Midi’s medication price table says there is no membership fee. That is helpful, but it does not mean there is no recurring clinical expense. Ask how frequently your clinician expects follow-up and whether laboratory work creates another charge. A patient who needs several visits will have a different budget from someone comparing only a four-week medication refill.

For a simple illustration, a $250 self-pay intake plus a $210 four-week injectable supply totals $460 before any other charges. This is arithmetic using published starting prices, not an individualized treatment quote or a prediction of later doses.

Injectable prices rise with the prescription

Midi’s pricing table lists a compounded dual-action GLP-1/GIP injectable from $210 to $434 per four-week supply, depending on dose. Shipping and supplies are included in the listed medication price. The table uses several dose bands; a person comparing providers should request the row matching the actual prescription rather than assuming the minimum lasts throughout treatment.³

A four-week supply also means a refill schedule may differ from calendar-month billing. Ask for the next charge date and expected shipment quantity, especially when comparing a provider that bills every twelve weeks or displays a monthly equivalent. These differences can matter even when two headline prices look close.

Midi separately offers branded prescriptions through a pharmacy pathway. Brand-name medication has its own coverage and cash-price considerations and should not be assigned the compounded product’s price.¹ If you want Zepbound specifically, confirm the product and pharmacy before comparing costs using our Zepbound savings guide.

Oral drops are a different decision

The current price table lists compounded sublingual dual-action medication from $209 to $460 per four-week supply. A separate oral-tirzepatide product page advertises a $199 starting amount. We found that discrepancy and have used the detailed pricing table for the comparison, while recommending confirmation of the exact offer.³⁴

The oral page describes drops placed under the tongue and acknowledges variable absorption. Its expectation of similar efficacy should not be read as proof of equivalence with approved injectable tirzepatide. We did not find a direct comparative clinical study supporting that equivalence in the reviewed product materials.⁴

This distinction matters more than a small price difference. Do not compare oral milligrams with injection milligrams as if they were interchangeable, or change a formulation or dose yourself. If avoiding injections is your priority, ask your clinician about the evidence for the proposed formulation, what benefit can reasonably be expected and which alternatives have stronger supporting evidence.

FDA states that compounded GLP-1 drugs are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. A provider’s care model or pharmacy relationship does not change that regulatory distinction.⁸

Pharmacy transparency and follow-up

Midi’s medication product page describes an intake, laboratory work when needed and follow-up for treatment adjustments. Its legal terms identify Precision Compounding Pharmacy in prescription fulfillment arrangements. That named relationship is useful information, but does not establish which pharmacy will fill every individual prescription or independently verify its current licensing.⁵⁶

Before accepting a compounded prescription, ask for the dispensing pharmacy, exact ingredients, concentration, storage instructions and contact details for a dispensing problem. Confirm where medication questions go after delivery. A clinician’s treatment decision and a pharmacy’s preparation and shipment are related but distinct responsibilities.

Midi’s main potential advantage is continuity with other midlife concerns. If you already want that broader clinical relationship, coordinating weight treatment there may reduce fragmented care. If you only want a low advertised drug price, the additional visits and dose-dependent medication costs may make a different model easier to budget.

Renewals, cancellation and prescription refunds

Midi’s terms state that subscription products renew automatically and require cancellation at least two days before processing. Cancellation generally takes effect at the end of the current period, with no ordinary refund for a partly used subscription period. Its prescription refund policy says medication is not returnable or refundable; dispensing problems should be taken to support.⁶⁷

Confirm whether your particular prescription uses automatic refills and distinguish its schedule from appointment billing. The site also sells other products, so a supplement-store cancellation rule should not be assumed to govern your prescription. Keep the refill policy attached to the order you actually place.

Who should compare Midi more closely?

Midi merits consideration when women’s midlife care and potentially insured visits are central to the decision. Its limitations are a multi-part bill, varying medication prices and the need for particular caution when interpreting oral-compound marketing. We have not tested appointment availability, clinical responsiveness or fulfillment speed.

Compare Ro if you want a branded pathway organized around a care membership, and Mochi for a different ongoing-care model. Check the tirzepatide evidence guide before treating medication convenience or a provider’s website claims as evidence of clinical equivalence.

This review assesses published program information, not firsthand treatment experience.